Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Stafylidis, Christos [1 ]
Vlachopoulou, Dimitra [1 ]
Kontandreopoulou, Christina-Nefeli [1 ]
Diamantopoulos, Panagiotis T. [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Internal Med 1, Hematol Unit, Athens 11527, Greece
来源：
JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 04期
关键词：
acute myeloid leukemia; TP53; mutations; TP53-mutated acute myeloid leukemia; novel targeted AML therapies; AML immunotherapies; HIGH-DOSE CYTARABINE; OLDER PATIENTS; MUTANT P53; THERAPEUTIC TARGET; COMPLEX KARYOTYPE; DRIVE CANCER; STEM-CELLS; AML; AZACITIDINE; TP53;
D O I：
10.3390/jcm13041082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Acute myeloid leukemia (AML) remains a challenging hematologic malignancy. The presence of TP53 mutations in AML poses a therapeutic challenge, considering that standard treatments face significant setbacks in achieving meaningful responses. There is a pressing need for the development of innovative treatment modalities to overcome resistance to conventional treatments attributable to the unique biology of TP53-mutated (TP53(mut)) AML. This review underscores the role of TP53 mutations in AML, examines the current landscape of treatment options, and highlights novel therapeutic approaches, including targeted therapies, combination regimens, and emerging immunotherapies, as well as agents being explored in preclinical studies according to their potential to address the unique hurdles posed by TP53(mut) AML.
引用
收藏
页数：21
相关论文
共 50 条
  • [21] Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Pillai, Raju
    Shouse, Geoffrey
    Sanchez, James F.
    Mei, Matthew
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) : E45 - E48
  • [22] TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations
    DiGennaro, Jeremy
    Sallman, David A.
    ACTA HAEMATOLOGICA, 2024, 147 (02) : 176 - 186
  • [23] TP53 mutated acute myeloid leukemia
    Sill, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 257 - 257
  • [24] Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53-Mutated Acute Myeloid Leukemia
    Jamy, Omer H.
    Diebold, Kendall
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Godby, Kelly N.
    Salzman, Donna
    Bhatia, Ravi
    BLOOD, 2022, 140 : 8959 - 8960
  • [25] Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin
    Wang, Yin
    Liu, Yan
    Bailey, Christopher
    Zhang, Huixia
    He, Miao
    Sun, Duxin
    Zhang, Peng
    Parkin, Brian
    Baer, Maria R.
    Zheng, Pan
    Malek, Sami N.
    Liu, Yang
    ONCOGENE, 2020, 39 (14) : 3015 - 3027
  • [26] Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin
    Yin Wang
    Yan Liu
    Christopher Bailey
    Huixia Zhang
    Miao He
    Duxin Sun
    Peng Zhang
    Brian Parkin
    Maria R. Baer
    Pan Zheng
    Sami N. Malek
    Yang Liu
    Oncogene, 2020, 39 : 3015 - 3027
  • [27] TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
    Daver, Naval G.
    Maiti, Abhishek
    Kadia, Tapan M.
    Vyas, Paresh
    Majeti, Ravindra
    Wei, Andrew H.
    Garcia-Manero, Guillermo
    Craddock, Charles
    Sallman, David A.
    Kantarjian, Hagop M.
    CANCER DISCOVERY, 2022, 12 (11) : 2516 - 2529
  • [28] Genomic landscape of TP53-mutated myeloid malignancies
    Abel, Haley J.
    Oetjen, Karolyn A.
    Miller, Christopher A.
    Ramakrishnan, Sai M.
    Day, Ryan B.
    Helton, Nichole M.
    Fronick, Catrina C.
    Fulton, Robert S.
    Heath, Sharon E.
    Tarnawsky, Stefan P.
    Srivatsan, Sridhar Nonavinkere
    Duncavage, Eric J.
    Schroeder, Molly C.
    Payton, Jacqueline E.
    Spencer, David H.
    Walter, Matthew J.
    Westervelt, Peter
    Dipersio, John F.
    Ley, Timothy J.
    Link, Daniel C.
    BLOOD ADVANCES, 2023, 7 (16) : 4586 - 4598
  • [29] TP53-mutated Acute Myeloid Leukemia with Myelodysplasia-Related Changes and TherapyRelated Acute Myeloid Leukemia Have Comparable TP53 Mutational Signature and Clinical Features
    Tashakori, Mehrnoosh
    Tapan, Kadia
    Loghavi, Sanam
    Tang, Zhenya
    Routbort, Mark
    Ravandi-Kashani, Farhad
    Khoury, Joseph
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1027 - 1028
  • [30] Treatment outcomes for newly diagnosed, untreated TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis.
    Daver, Naval Guastad
    Iqbal, Shahed
    Renard, Camille
    Chan, Rebecca J.
    Hasegawa, Ken
    Hu, Hao
    Tse, Preston
    Yan, Jiajun
    Zoratti, Michael J.
    Xie, Feng
    Ramsingh, Giridharan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19020 - E19020
12345